Our understanding of the etiology of EGFR-mutant lung cancer remains incomplete. One persistent finding in the literature is the geographic variation in the frequency of EGFR mutations in lung adenocarcinoma. We investigated the association between two biomarkers of East Asian ancestry, the genetic polymorphisms ectodysplasin A receptor gene (EDAR) V370A and ATP binding cassette subfamily C member 11 gene (ABCC11) G180A, and the frequency of EGFR mutations in patients with lung adenocarcinoma in a range of countries. The Pearson's linear correlation between the frequency of EGFR mutations and the EDAR polymorphism was 0.92 (p <2.2 Â 10 -10 ), and for the ABCC11 polymorphism it was 0.72 (p <1.6 Â 10 -4 ). These results suggest that the variation in the measured frequency of EGFR mutations in lung adenocarcinoma can be explained, at least in part, by interethnic genetic variation. To improve our understanding of this disease, studies exploring the genetic polymorphism(s) that cause these interethnic differences, as well as the mechanisms of actions through which they work, are warranted.
Introduction
Lung cancer claims 1.6 million lives worldwide every year. 1 Smoking is recognized as the main risk factor, but the disease also affects never-smokers. A range of environmental factors other than smoking, as well as genetic susceptibility, have been suggested to play a role in the etiology of the disease. 1 It has recently also been proposed that many of the mutations observed in cancer are the result of random DNA replication mistakes occurring when normal noncancerous stem cells divide. 2 The relative importance of such random DNA replication mistakes, inherited genetic susceptibility, and environmental factors in the etiology of lung cancer affecting never-smokers remains to be determined.
One of the most frequently mutated genes in lung cancer is the EGFR gene. Mutations in this gene are most commonly observed in NSCLC of the adenocarcinoma histologic type and are more frequent in never-smokers than smokers. 3 A persistent finding in the literature is the significant geographic variation in the frequency of EGFR mutations. 4 Although such mutations are found in more than 40% of lung adenocarcinoma cases in Japan and China, they are found in only around 15% of cases in France and Italy. 5 It has been proposed that ethnicity may explain these differences. 6, 7 To investigate the potential role of interethnic genetic variation in the etiology of EGFR-mutant lung cancer, we analyzed the relationship between two genetic biomarkers of East Asian ancestry and the frequency of EGFR mutations in patients with lung adenocarcinoma in a range of countries.
Methods
As biomarkers for East Asian ancestry, we used the genetic polymorphisms EDAR V370A (rs3827760) and ABCC11 G180A (rs17822931). These polymorphisms were selected because they are established biomarkers of East Asian ancestry 8, 9 and because data on their frequency are available for many populations. It has not been reported that these polymorphisms themselves play any role in the etiology of lung cancer, and they are thus used solely as proxies for East Asian ancestry.
Frequency data for the EDAR and ABCC11 polymorphisms in different populations were taken from the ALlele FREquency Database (ALFRED). 10 For each of the polymorphisms, the database was screened for records matching the population of a country. If several records matching the same country were found, a weighted average was calculated by using sample sizes as weights.
EGFR mutation frequency in patients with lung adenocarcinoma was compiled from the literature for the countries for which data on either the EDAR or the ABCC11 polymorphism were available. The data reported in the Global EGFR Mutation Map II (MutMapII) were used as a starting point. 5 Where no EGFR frequency data were reported in MutMapII, or where MutMapII data were based on fewer than 500 patients, a literature search was done. If a more recent estimate based on a larger data set was found, this was used. Conference abstracts and non-English-language articles were excluded. Data for the frequency of EGFR mutations were used as reported in the underlying studies. No attempt was made to adjust for variation in the subtypes of EGFR mutations that had been included in the different studies.
Statistical Methods
All statistical analyses were carried out using MS Excel 2010 (Microsoft, Redmond, WA). Built-in functions for correlation and a two-sided Student's t-distribution were applied to provide the Pearson's correlation between the frequency of the two biomarkers (i.e., the EDAR V370A and the ABCC11 G180A polymorphisms) and the EGFR mutation frequency. Spearman's rho was calculated similarly by using the built-in rank function in Excel to provide ranked versions of the EDAR polymorphism, the ABCC11 polymorphism, and EGFR mutation frequencies. A confidence interval of 95% was set for all calculations.
Results
We identified 24 countries for which estimates were available for both the frequency of EGFR mutations in patients with lung adenocarcinoma and the populationwide frequency of the EDAR V370A polymorphism. For 22 countries we found data on both EGFR mutation frequency and frequency of the ABCC11 G180A polymorphism. The EGFR, EDAR, and ABCC11 samples in total were obtained from 35,411, 11,255, and 6029 people, respectively. Per-country data, including sample sizes, and the frequency of EGFR mutations and the EDAR and ABCC11 polymorphisms, as well as sources for the EGFR data, are provided in Supplementary Table 1 . Raw data and calculations are found in Supplementary Data File 1.
We first investigated the association between the frequency of the EDAR polymorphism and the frequency of EGFR mutations (Fig. 1) . The correlation between these two parameters was highly positive and significant. Spearman's rho was 0.82 (p <8
As shown by Figure 1 , the correlation is not limited to certain geographical regions. Furthermore, both more and less economically developed countries are found on each side of the spectrum. The association between EGFR mutation frequency and the EDAR polymorphism thus seems independent of the level of economic development.
We next did a similar analysis using the ABCC11 polymorphism (Fig. 2) . Although the association between this polymorphism and the frequency of EGFR mutations appears somewhat weaker, the correlation is still highly positive and significant. Spearman's rho was 0.71 (p <2.2 Â 10 ). As some of the data points used in the aforementioned analysis were based on small samples, we repeated the analysis with data points based on fewer than 50 people being excluded. The results did not substantially change (data not shown).
Discussion
Our results suggest that the reported geographic differences in the frequency of EGFR mutations in lung adenocarcinoma can be explained by interethnic genetic variation. Other data points, reported by others, provide further evidence for this.
Arrieta et al. investigated the frequency of EGFR mutations in patients with lung cancer in a number of Latin American countries. 11 They reported that whites in their data set had an EGFR mutation frequency of 14%, whereas the indigenous and mestizo (mixed race) population had an EGFR mutation frequency of 35%. This is consistent with indigenous Latin Americans being descendants of people who migrated from Asia around 15,000 years ago 12 and with data showing that these populations have a high frequency of the EDAR V370A polymorphism, as well as a relatively high frequency of the ABCC11 G180A polymorphism. 10 Furthermore, Soh et al. 6 studied 302 patients with lung adenocarcinoma from Japan, the United States, Canada, and Australia and found that EGFR mutations and copy number gains were more frequent in Asians than in whites. They also reported that the association was independent of sex and smoking status.
Further corroborating a link between ethnicity and EGFR mutation frequency are several small studies that have found high rates of EGFR mutations in patients with lung cancer of Asian descent who are living in North America. Our work extends previous work by other groups by covering a significantly larger number of countries and by explicitly linking the EGFR mutation frequency to biomarkers of East Asian ancestry. The use of biomarkers allows for a numerical estimate of how much of the geographic variation in EGFR mutation frequency is explained by genetic susceptibility versus by other factors. Our analysis indicates that interethnic genetic variation is the main determinant of the observed variation in EGFR mutation frequency. The relationship found appears valid across continents, across countries at different levels of economic development, and as reported by others, it appears independent of both sex and smoking status.
Our study has several limitations. We have measured correlations at the population level and not directly in individuals. This introduces several potential biases, as the samples used to estimate the population-wide frequencies of the EDAR and ABCC11 polymorphisms may not be representative of the overall population in the country. Furthermore, disparities in wealth, access to health care, and other factors may lead to biases in the EGFR mutation frequency estimates. The variation in the types of EGFR mutations included in the underlying studies is yet another weakness of our study.
The ever-increasing amount of sequencing data that are being generated, from both patients with cancer and healthy individuals, should facilitate further research in this area. Using such data to investigate the identified correlations at the level of individuals rather than populations may overcome some of the limitations of the present study. We appreciate that a lack of correlation at the level of individuals would be a refutation of our findings.
Assuming our results are not spurious, it also remains to be established which genetic polymorphism(s) cause the observed interethnic differences in EGFR mutation frequency and the mechanisms of action through which they work. To identify plausible polymorphisms, future genome-wide association studies may benefit from taking into account the fact that the most relevant polymorphisms likely occur with different frequencies in different ethnic groups.
When plausible candidates have been identified, mechanistic studies will be needed to gain a better understanding of their potential role in the etiology of EGFR-mutant lung cancer. Theoretically, genetic polymorphisms can contribute to variation in the frequency of EGFR mutations in patients with lung adenocarcinoma by affecting either the "seed" or the "soil."
15 Do the polymorphism(s) make lung cells in persons of East Asian ethnicity more prone to acquire activating EGFR mutations, thus creating more "seeds" that may go on to cause cancer? Or do they influence the "soil," for instance, by making the lung microenvironment in East Asians more permissive of EGFR-mutant cells or by conferring such mutant cells a greater selective advantage?
Further research in this area may provide valuable insight into the etiology of EGFR-mutant lung cancer and may ultimately contribute to better prevention and treatment of the disease.
